Phathom Pharmaceuticals, Inc. (PHAT) Stock Analysis & Investment Frameworks
Phathom Pharmaceuticals, Inc. (PHAT) stock analysis on Invetso. Review Phathom Pharmaceuticals, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Phathom Pharmaceuticals, Inc. Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Phathom Pharmaceuticals, Inc. Key Financial Metrics
- Market Cap: $426.78M
- Revenue: $175.11M
- ROE: 29.66%
- ROIC: -14.90%
- Dividend Yield: N/A
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.